<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323477</url>
  </required_header>
  <id_info>
    <org_study_id>741.STZ.2014</org_study_id>
    <nct_id>NCT02323477</nct_id>
  </id_info>
  <brief_title>Human Umbilical Cord Stroma MSC in Myocardial Infarction</brief_title>
  <acronym>HUC-HEART</acronym>
  <official_title>The Efficacy and Safety Assessment of Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction; a Phase 1/2 Clinical Trial (HUC-HEART Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hacettepe University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Turkiye Yuksek Ihtisas Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atigen-Cell and Tissue Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sami Ulus Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ankara Yildirim BeyazÄ±t University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this phase 1/2 clinical trial is to evaluate the efficacy and safety of&#xD;
      allogeneic human umbilical cordstroma derived multipotent stem cells (hUCS-MSCs) in&#xD;
      myocardial infarction (MI). All subjects will be taken into the bypass coronary surgery prior&#xD;
      to the cell administration. This 2-year study comprise three independent groups, where the&#xD;
      first group (n=20) will take no cells, second group will take autologous BM-MNCs (n=20), and&#xD;
      third group (n=39) will be receiving allogeneic hUCS-MSCs. In all transplantations cells will&#xD;
      be administered to the approximately 10 peri-infarct areas at one time. The infarct zone will&#xD;
      be determined by the MR, SPECT and PET imaging. Only male subjects between 30-80 years of&#xD;
      age. The efficiency of the therapy will be evaluated according to the parameters measured by&#xD;
      MR, SPECT, and Echocardiography. All subject were taken into those measurements prior and 6,&#xD;
      12, 18 and 24 months after the operation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to budget limitations as allocated for a given period.&#xD;
  </why_stopped>
  <start_date type="Actual">February 2, 2015</start_date>
  <completion_date type="Actual">December 30, 2018</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ventricular remodeling</measure>
    <time_frame>within one year after cell transplantation</time_frame>
    <description>Outcome measures will be determined by cardiac MR, SPECT and PET monitoring to assess the left ventricular ejection fraction (%), left ventricle end-diastolic and end-systolic volumes (mL/m2), left ventricle mass (g/m2), infarct size (%), and the thickness of the dysfunctional wall (mm).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Chronic Ischemic Cardiomyopathy</condition>
  <condition>Coronary Artery Bypass Surgery</condition>
  <arm_group>
    <arm_group_label>Allogeneic umbilical cord MSC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic human umbilical cord MSCs will be transplanted to 39 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF&lt;%45)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autologous bone marrow-derived MNC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Autologous bone marrow-derived MNCs will be transplanted to 20 male patients (age 30-80) intramyocardially during CABG in chronic ischemic cardiomyopathy (EF&lt;%45)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>20 male patients (age 30-80) undergoing CABG in chronic ischemic cardiomyopathy (EF&lt;%45) whom will not received any further transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation</description>
    <arm_group_label>Allogeneic umbilical cord MSC group</arm_group_label>
    <arm_group_label>Autologous bone marrow-derived MNC group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ischemic hearth disease who will experience CABG&#xD;
&#xD;
          -  %25&lt;EF&lt;%45&#xD;
&#xD;
          -  NYHA class II-IV patients&#xD;
&#xD;
          -  hemodynamically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient's in approval&#xD;
&#xD;
          -  Acute cardiac decompensation&#xD;
&#xD;
          -  Acute myocardial infarction&#xD;
&#xD;
          -  Congenital heart disease&#xD;
&#xD;
          -  Additional surgical heart disease other than coronary artery disease&#xD;
&#xD;
          -  Malign arrhythmia&#xD;
&#xD;
          -  All malignancies&#xD;
&#xD;
          -  HbA1c level &gt;%10 (86 mmol/mol) type II diabetes mellitus&#xD;
&#xD;
          -  Severe liver dysfunction&#xD;
&#xD;
          -  Severe COPD&#xD;
&#xD;
          -  Coagulopathy&#xD;
&#xD;
          -  Immunosuppressive treatment&#xD;
&#xD;
          -  Acute hepatitis, hepatitis B, C and HIV infection&#xD;
&#xD;
          -  Chronic liver and renal failure&#xD;
&#xD;
          -  Collagen tissue disease&#xD;
&#xD;
          -  Stroke&#xD;
&#xD;
          -  TB&#xD;
&#xD;
          -  Hematological diseases&#xD;
&#xD;
          -  Socially and mentally disabilities&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alp Can</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 18, 2014</study_first_submitted>
  <study_first_submitted_qc>December 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara University</investigator_affiliation>
    <investigator_full_name>Alp Can</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>cellular therapy</keyword>
  <keyword>chronic ischemic heart disease</keyword>
  <keyword>phase 1/2 clinical study</keyword>
  <keyword>human umbilical cord multipotent stem cell</keyword>
  <keyword>human umbilical cord mesenchymal stem cell</keyword>
  <keyword>ischemic heart disease</keyword>
  <keyword>bone marrow mononuclear cell</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

